PROK ProKidney
- 3.480
- -0.720-17.14%
- 3.470
- -0.010-0.29%
ProKidney News
ProKidney Phase 2 Trial Success Sparks Investor Interest
ProKidney to Participate in the Jefferies Global Healthcare Conference
WINSTON-SALEM, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced
ProKidney Is Maintained at Neutral by B of A Securities
ProKidney Is Maintained at Neutral by B of A Securities
B of A Securities Maintains Neutral on ProKidney, Raises Price Target to $4
B of A Securities analyst Jason Gerberry maintains ProKidney with a Neutral and raises the price target from $3 to $4.
ProKidney Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/29/2024 2.86% B of A Securities $3 → $4 Maintains Neutral 03/07/2024 -22.86% Morgan Stanley → $3 Assume
Buy Rating Affirmed for ProKidney on Rilparencel's Promising Efficacy in CKD Treatment
Maintaining Hold on ProKidney: Balancing Market Potential Against Clinical Uncertainties
ProKidney(PROK.US) Officer Sells US$70,386.2 in Common Stock
$ProKidney(PROK.US)$ Officer Weber Darin J. sold 17,238 shares of common stock on May 20, 2024 at an average price of $4.0832 for a total value of $70,386.2.Source: Announcement What is statement of c
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data From Phase 2 RMCL-002 Clinical Trial on May 28, 2024
WINSTON-SALEM, N.C., May 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic ki
Form 144 | ProKidney(PROK.US) Officer Proposes to Sell 279.6K in Common Stocks
SEC FILLINGS DISCLOSED/ May 20, $ProKidney(PROK.US)$ Officer DARIN J WEBER intends to sell 68,952 shares of its common stock on May 20, with a total market value of approximately $279.6K. DARIN J WE
ProKidney(PROK.US) 10% Shareholder Buys US$251.67K in Common Stock
$ProKidney(PROK.US)$ 10% Shareholder Control Empresarial de Capitales S.A. de C.V. purchased 177K shares of common stock on Mar 13, 14, 20, 22, 25, 2024 at an average price of $1.4218 for a total valu
JAN, MTC and PROK Among Mid-day Movers
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersDelcath Systems (NASDAQ:DCTH) stock rose 33.2% to $7.19 during Tuesday's regular session. The company's market cap stands at $199.8 million. As per the news, the Q1 earnings report came out tod
Shares of 'Meme Stocks' and High-short Interest Stocks Are Trading Higher Amid a Renewed Surge in the Space After Popular Retail Trader 'Roaring Kitty' Returned to Social Media.
Shares of 'Meme Stocks' and High-short Interest Stocks Are Trading Higher Amid a Renewed Surge in the Space After Popular Retail Trader 'Roaring Kitty' Returned to Social Media.
Here's Why We're Not Too Worried About ProKidney's (NASDAQ:PROK) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring
Stocks With More Than 10% Short Interest - Finviz Screener
We're Hopeful That ProKidney (NASDAQ:PROK) Will Use Its Cash Wisely
ProKidney | 10-Q: Quarterly report
ProKidney (PROK.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share were -0.16 dollars, previous value was -0.16 dollars, and expected value was -0.18 dollars.
ProKidney (PROK.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share were -0.16 dollars, previous value was -0.16 dollars, and expected value was -0.18 dollars.
ProKidney Q1 Loss Unchanged From Year Earlier
ProKidney (PROK) reported a Q1 net loss Friday of $0.16 per diluted share, unchanged from a year earlier. Two analysts polled by Capital IQ had forecast a Q1 GAAP loss of $0.35 per share. As expected,
Analysis
Price Target
No Data
